ArticleHaematologica2019

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Chiara Tarantelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.